12/01/2022 - PharmaFrontiers Appoints Mathilda Mandel to Clinical Advisory Board

11/15/2005 - PharmaFrontiers Shareholders Approve Increase in Authorized Shares at Special Meeting

11/15/2005 - PharmaFrontiers Reports Third Quarter 2005 Financial Results; Provides Update on Research ...

11/09/2022 - PharmaFrontiers Corp. Selects MDB Capital Group as Financial Advisor

11/08/2022 - PharmaFrontiers Corp Elects Brooks Boveroux as Chairman; To Assume Primary Responsibility...

11/02/2022 - PharmaFrontiers Corp. to Present at Rodman & Renshaw Techvest Seventh Annual Healthcare Conference

11/01/2022 - PharmaFrontiers Corp. Reconstitutes Its Audit Committee

10/31/2005 - PharmaFrontiers Tovaxin(TM) Phase IIb Multiple Sclerosis Clinical Trial Protocol Accepted by FDA

10/26/2005 - PharmaFrontiers Corp. Elects Interim Chairman

10/25/2005 - PharmaFrontiers Corp. to Present at the PIPEs Conference 2005

10/18/2005 - PharmaFrontiers Corp. Names Brooks Boveroux to Board of Directors

10/17/2005 - PharmaFrontiers Corp. to Present at the 2005 BIO Emerging Company Investor Forum

10/03/2022 - PharmaFrontiers Presents Positive Tovaxin(TM) Research at International Multiple Sclerosis Meeting

09/22/2005 - PharmaFrontiers Cancels Presentation Due to Hurricane Rita

09/21/2005 - PharmaFrontiers to Present at Sanders Morris Harris Growth Conference

09/13/2005 - PharmaFrontiers to Present at ValueRich Small Cap Financial Exposition

08/16/2005 - PharmaFrontiers Reports Second Quarter 2005 Financial Results; Provides Research Update

08/10/2021 - PharmaFrontiers to Present Tovaxin(TM) Research at International Multiple Sclerosis Meeting

07/27/2005 - PharmaFrontiers Plans to Ask SEC for Accelerated Effective Date

06/20/2005 - PharmaFrontiers Completes $5.08 MM Financing

06/08/2022 - PharmaFrontiers Presented Preliminary Tovaxin Clinical Plans at Multiple Sclerosis Centers Meeting

06/03/2022 - PharmaFrontiers Announces Positive Interim Results of Two Phase I/II Clinical Trials for Multiple Sclerosis

05/17/2005 - PharmaFrontiers Adds Three Members to Its Scientific Advisory Board

05/03/2022 - PharmaFrontiers Selects INC Research as Development Partner for its Novel Multiple Sclerosis Therapy

04/26/2005 - PharmaFrontiers Announces Dr. Eliezer Huberman to Chair Scientific Advisory Board

04/15/2005 - PharmaFrontiers Provides Update, Financial Results